We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Y mAbs Therapeutics Inc | NASDAQ:YMAB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.76 | 4.61% | 17.25 | 15.60 | 17.22 | 17.39 | 16.295 | 16.49 | 376,468 | 22:30:00 |
From May 2022 to May 2024
By Chris Wack
Y-mAbs Therapeutics Inc. said Tuesday that the biologics license application for Omblastys (omburtamab) for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma has been accepted for priority review by the U.S. Food and Drug Administration.
The FDA set an action date of Nov. 30, 2022, under the Prescription Drug User Fee Act, and indicated it is planning to hold an advisory committee meeting in October 2022 to discuss the application, Y-mAbs said.
Omblastys has a rare pediatric disease designation which, if approved, will provide Y-mAbs with a priority review voucher.
Researchers at Memorial Sloan Kettering Cancer Center developed omburtamab, which is exclusively licensed by MSK to Y-mAbs. As a result of the licensing arrangement, MSK has institutional financial interests in the compound and in Y-mAbs.
Y-mAbs shares rose 7% to $12.50 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 31, 2022 09:39 ET (13:39 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Y mAbs Therapeutics Chart |
1 Month Y mAbs Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
